Evidence map›Paper›PMID 41144262›Full record

ArticleCarcinogenesis2025

Symposium report-ethical and social considerations regarding return of secondary findings in atomic bomb survivors.

Noriaki Yoshida, Douglas R Stewart, Arikuni Uchimura, Ken-Ichi Arita, Yvonne Bombard, Megan Frone, Takao Hinoi, Kenji Kamiya, Shigeru Katamine, Junji Kayukawa and 13 more

Abstract read
In one paragraph

Article in Carcinogenesis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Noriaki YoshidaDepartment of Clinical Studies, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0001-7001-0106
Douglas R StewartClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.ORCID 0000-0001-8193-1488
Arikuni UchimuraDepartment of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0003-2435-7082
Ken-Ichi AritaHiroshima Atomic Bomb Nursing Home Funairi Mutsumi-en, Hiroshima 730-0844, Japan.
Yvonne BombardInstitute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada M5T 1P8.ORCID 0000-0002-9516-4539
Megan FroneClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20850, USA.ORCID 0000-0001-8273-8866
Takao HinoiDepartment of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima 734-0037, Japan.
Kenji KamiyaRadiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0002-5801-7310
Shigeru KatamineNagasaki University, Nagasaki 852-8501, Japan.
Junji KayukawaDepartment of Social System Design, Eikei University of Hiroshima, Hiroshima 730-0016, Japan.
Kazunori KodamaRadiation Effects Research Foundation, Hiroshima 732-0815, Japan.
David T MillerDivision of Genetics and Genomics, Boston Children's Hospital, Boston, MA 02115, USA.ORCID 0000-0003-1060-1945
Kiyonori MiuraDepartment of Obstetrics and Gynecology, Nagasaki University Graduate School of BioMedical Sciences, Nagasaki 852-8501, Japan.
Kaori MutoDepartment of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Fuji NagamiTohoku Medical Megabank Organization, Tohoku University, Sendai, Miyagi 980-8573, Japan.ORCID 0000-0002-3652-9788
Hidewaki NakagawaLaboratory for Cancer Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.ORCID 0000-0003-1807-772X
Asao NodaDepartment of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0002-9029-9813
Waka OhishiDepartment of Clinical Studies, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0003-3195-4045
Osamu TanabeDepartment of Molecular Biosciences, Radiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0001-8103-7822
Chikashi TeraoLaboratory for Statistical and Translational Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa 230-0045, Japan.ORCID 0000-0002-6452-4095
Preetha RajaramanRadiation Effects Research Foundation, Hiroshima 732-0815, Japan.ORCID 0000-0001-6649-999X
Kazuto KatoDepartment of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.ORCID 0000-0001-9006-9551
Leslie G BieseckerMedical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Funding

MHLW DE-HS0000031National Academy of SciencesNIH HHS HG200387-11
6 · The paper itself

Abstract

The Radiation Effects Research Foundation (RERF) conducts research on the health effects of atomic bomb (A-bomb) radiation, supported by the long-term cooperation of survivors and their children. In response to concerns from A-bomb survivors, their offspring, and the global community, RERF has investigated transgenerational radiation effects for many years. Currently, RERF is planning the Trio Genome Study (TGS), which will utilize advanced genome sequencing to examine potential genetic effects on the offspring of survivors. This study could yield significant findings but also presents ethical challenges, particularly in ensuring that results are returned responsibly to the community. RERF first held an international workshop to address ethical, legal, and social issues related to genomic analysis in 2020, followed by formation of stakeholder committees to align the study with community perspectives. Most recently, in December 2024, an international symposium further explored frameworks important to the TGS, including risk communication, benefit-sharing, community involvement, and return of secondary findings. In genomic analysis, secondary findings comprise a deliberate search for pathogenic variants in an established list of genes in disorders associated with life-threatening manifestations. Returning these secondary findings to research participants is crucial from the perspective of benefit-sharing. Discussions emphasized the need for transparency in the return of secondary findings, especially those with actionable health implications, including sharing the rationale behind providing information about genetic variants to research participants. These frameworks will guide not only future RERF studies but also genomic research worldwide, ensuring that the findings benefit participants and communities.

Indexed as

Atomic Bomb SurvivorsGenomicsHumansNuclear WeaponsELSIGenome studyreturn of secondary findings

Identifiers

PMID41144262
PMCPMC12558142

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.